Bioventix PLC
BVXP
Company Profile
Business description
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country.
Contact
27–28 Eastcastle Street
LondonW1W 8DH
GBRSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
17
Stocks News & Analysis
stocks
Chart of the Week: Opportunities with wide-moat retailers
Consumer defensive names look undervalued.
stocks
New ASX share added to our best ideas
Earnings outlook is strong and the shares trade at a discount to our fair value.
stocks
Fair value downgraded for ASX heavyweight
Our capital allocation rating was also lowered due to balance sheet weakness.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,190.20 | 7.50 | -0.08% |
| CAC 40 | 7,966.95 | 71.01 | 0.90% |
| DAX 40 | 24,113.62 | 232.90 | 0.98% |
| Dow JONES (US) | 46,441.10 | 43.21 | 0.09% |
| FTSE 100 | 9,446.43 | 96.00 | 1.03% |
| HKSE | 26,855.56 | 232.68 | 0.87% |
| NASDAQ | 22,755.16 | 95.15 | 0.42% |
| Nikkei 225 | 44,783.24 | 232.39 | 0.52% |
| NZX 50 Index | 13,423.64 | 10.35 | -0.08% |
| S&P 500 | 6,711.20 | 22.74 | 0.34% |
| S&P/ASX 200 | 8,899.60 | 6.20 | -0.07% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |